REG - Kanabo Group PLC - Directorate Change

KanaboAnnouncement

31/03/2023 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230331:nRSe9997Ua&default-theme=true

RNS Number : 9997U  Kanabo Group PLC  31 March 2023

 

31 March 2023

 

Kanabo Group plc

("Kanabo", the "Group" or the "Company")

 

Directorate Change

 

Kanabo Group plc (LSE: KNB), a leading patient-focused healthtech ecosystem
and provider of personalised medicinal treatments, announces that Dan Poulter
has stepped down as Non-Executive Director ("NED") to focus on existing
commitments outside of the business.

 

Kanabo is at very advanced stages of appointing a new UK-based NED to join the
Board of Directors, and a further announcement about this will be made
imminently.

 

David Tsur, Chairman of Kanabo, commented:

 

"I would like to thank Dan for his contribution to the Company. He has been a
pleasure to work with and we wish him every success in the future."

 

 

Enquiries:

 

 Kanabo Group plc                                                  via Vigo Consulting

 Avihu Tamir, Chief Executive Officer                              +44 (0)20 7390 0230

 Assaf Vardimon, Chief Financial Officer

 Peterhouse Capital Ltd (Financial Adviser and Broker)             +44 (0)20 7469 0930

 Eran Zucker/ Lucy Williams / Charles Goodfellow

 Vigo Consulting (Financial Public Relations/Investor Relations)    +44 (0)20 7390 0230

 Jeremy Garcia / Fiona Hetherington / Verity Snow

 kanabo@vigoconsulting.com

 

 

About Kanabo Group Plc

Founded in 2017, Kanabo Group Plc (LSE:KNB) is a patient-first HealthTech
ecosystem, focused on delivering high quality and innovative medical
treatments, via its leading-edge technology platform and disruptive product
offering.

 

The Company is a world leader in the research, development and
commercialization of regulated medicinal cannabis-derived formulations and
therapeutic inhalation devices.

 

Patient care is delivered via the company's NHS-approved online telehealth
platform offering video consultations, online prescriptions and access to
primary care services.  In January 2023, the Company successfully combined
its technological and product expertise to launch the Beta phase of its
medical cannabis business, initially for chronic pain management, under the
new Treat-It brand.

 

Kanabo Group is committed to evolving more accessible healthcare experiences
for every patient.

 

Visit www.kanabogroup.com (http://www.kanabogroup.com)  for more info.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFLFVVVIILVIV